drugset / Trial / NCT06846515
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
Timeline
- Start
- 2025-03-11
- Primary completion
- 2026-09
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AR882 | Unknown | 50 mg | Oral |
| Subject | AR882 | Unknown | 75 mg | Oral |